Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Psychometric characteristics of the ankylosing spondylitis quality of life questionnaire, short form 36 health survey, and functional assessment of chronic illness therapy-fatigue subscale
Dennis A Revicki, Anne M Rentz, Michelle P Luo, Robert L Wong, Lynda C Doward, Stephen P McKenna
Health and Quality of Life Outcomes , 2009, DOI: 10.1186/1477-7525-7-6
Retraction: Psychometric characteristics of the ankylosing spondylitis quality of life questionnaire, short form 36 health survey, and functional assessment of chronic illness therapy-fatigue subscale
Dennis A Revicki, Anne M Rentz, Michelle P Luo, Robert L Wong, Lynda C Doward, Stephen P McKenna
Health and Quality of Life Outcomes , 2009, DOI: 10.1186/1477-7525-7-34
Abstract: Not all authors approved of the final content or publication of this article [1]. Subsequently, all authors have agreed that the article should be retracted. This article is being retracted as assumptions were made about the nature of the outcome data that should have been tested before the analyses were conducted. In addition, there is disagreement among the authors about the statistical analyses that were used and it is possible that incorrect conclusions may have been drawn that are not supported by the data presented. The authors wish to apologise for any inconvenience this may have caused the editorial, publishing staff and readers.
Priyanka Lokwani*,Yozana Upadhyay,Pramod Kumar,Stuti Gupta
Pharmacie Globale : International Journal of Comprehensive Pharmacy , 2011,
Abstract: Ankylosing spondylitis (AS) is a chronic, progressive, connective tissue disorder that is characterized by inflammation of the joints of the spine (vertebral joints), hipbones, and sacrum (sacroiliac joints). There is no cure for ankylosing spondylitis, but treatments can decrease pain and lessen symptoms. Treatment includes pain relieving drugs, DMARDs and TNFα blockers; herbal and homeopathic medications are also available.
Andersson Lesion in Ankylosing Spondylitis
Manimegalai N, KrishnanKutty K, Panchapakesa Rajendran C, Rukmangatharajan S, Rajeswari S
JK Science : Journal of Medical Education & Research , 2004,
Abstract: Andersson lesions are destructive foci that appear at the discovertebral junction in ankylosingspondylitis. We report three cases of ankylosing spondylitis with such lesions. These lesions simulatean infection and in our country, mimic spinal tuberculosis.
The Association of Acromegaly and Ankylosing Spondylitis
Alpaslan Tuzcu,Ayse Dicle Turhanoglu,Mithat Bah?eci,Hatice ?ztürkmen Akay
Dicle Medical Journal , 2004,
Abstract: Coexistence of acromegaly and anklosing spondylitis had been rarelyreported. Only two case reports were described coexistence of two diseasesin literature. These two diseases have some similar clinical andradiographic features. Calcaneal epin formation, enteshopathy and caudeequina syndrome can be seen both acromegaly and ankylosing spondylitis.Our case had clinical and radiological features of both acromegaly andankylosing spondylitis. Acral enlargement, coarsening of feature,malocclusion, non-suppressed growth hormone levels with oral glucosetolerance test and evidence of pituitary adenoma were support diagnose ofacromegaly. Morning stiffness, positive Schober and Moll test, elevatederythrocyte sedimentation rate and grade 4 sacroiletis of the patient lead usto diagnose ankylosing spondylitis at the same time. In this case report, weaim to discuss interesting coexistence of two disease
Cardiopulmonary Manifestations of Ankylosing Spondylitis  [PDF]
Mahnaz Momeni,Nora Taylor,Mahsa Tehrani
International Journal of Rheumatology , 2011, DOI: 10.1155/2011/728471
Abstract: Ankylosing spondylitis is a chronic inflammatory condition that usually affects young men. Cardiac dysfunction and pulmonary disease are well-known and commonly reported extra-articular manifestation, associated with ankylosing spondylitis (AS). AS has also been reported to be specifically associated with aortitis, aortic valve diseases, conduction disturbances, cardiomyopathy and ischemic heart disease. The pulmonary manifestations of the disease include fibrosis of the upper lobes, interstitial lung disease, ventilatory impairment due to chest wall restriction, sleep apnea, and spontaneous pneumothorax. They are many reports detailing pathophysiology, hypothesized mechanisms leading to these derangements, and estimated prevalence of such findings in the AS populations. At this time, there are no clear guidelines regarding a stepwise approach to screen these patients for cardiovascular and pulmonary complications. 1. Cardiac Manifestations of Ankylosing Spondylitis Introduction Ankylosing spondylitis is a chronic and inflammatory condition, affecting the spine, sacroiliac, and peripheral joints. This entity most often affects young men and may lead to spinal vertebral fusion. Human leukocyte antigen (HLA)-B27 is present in the majority of patients with AS and is reported to contribute to the pathophysiologic manifestations of this condition [1]. It has been estimated that cardiac manifestations in patients with AS are found in 2–10% of patients. It was initially in the 1930s when aortitis found in a group of patients with spondylitis. It is widely accepted today that not only is aortic pathology linked to AS, but there is also risk for conduction defects, valvular regurgitation, and cardiomyopathy, associated with this entity [1]. This is especially important, given that in many patients, cardiac changes may begin prior to the onset of clinical symptoms [2, 3]. 1.1. Valvular Disease The presence of aortic root and valve disease in ankylosing spondylitis is related to the duration of the underlying disease. Aortic disease and aortic regurgitation may, however, predate the onset of any joint symptoms, and the presence of ankylosing spondylitis as an underlying cause may not be initially appreciated [1]. One of the first pathophysiologic descriptions of valvular disease in AS was put forward by Bulkley and Roberts, who studied autopsy findings in eight patients with AS. They noted aortic root dilatation along with fibrous proliferation along the intima [4]. Further examination demonstrated a cellular inflammatory process coupled with platelet aggregation
Ankylosing Spondylitis Related Spondylodiscitis
?i?dem Atan,ümit Se?kin,Hatice Bodur
Türkiye Fiziksel Tip ve Rehabilitasyon Dergisi , 2008,
Abstract: Spondylodiscitis is a well recognized but uncommon complication of Ankylosing Spondylitis (AS). It usually occurs in advanced stages of AS. The clinical presentation of spondylodiscitis may vary from asymptomatic to symptoms of serious spinal cord injury. Here we presented a case with chronic low back pain who was not diagnosed as AS earlier and who had wide-spread spondylodiscitis when diagnosed. Turk J Phys Med Rehab 2008;54:77-8
Disseminated Tuberculosis Mimicking Ankylosing Spondylitis
Valérie Huyge,Serge Goldman,Muhammad S. Soyfoo
Case Reports in Rheumatology , 2011, DOI: 10.1155/2011/195085
Abstract: Ankylosing spondylitis is a chronic inflammatory disorder affecting mainly the axial skeleton. Here we report a case of a man with a clinical suspicion of ankylosing spondylitis but with a persistence of increased inflammatory markers. In this case, 18F-FDG-PET/CT revealed multiple hypermetabolic lesions in axial skeleton, lymph nodes, and the lung, suggestive of either disseminated tuberculosis or lymphoma. Histological analysis of the pulmonary lesion revealed mycobacterium tuberculosis. This case highlights, firstly, the importance of excluding other diagnoses in the presence of clinical picture of ankylosing spondylitis and high inflammatory markers and, secondly, the determining role of PET/CT.
Validation of the Italian versions of the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Dougados Functional Index (DFI) in patients with ankylosing spondylitis  [cached]
F. Salaffi,A. Stancati,A. Silvestri,M. Carotti
Reumatismo , 2011, DOI: 10.4081/reumatismo.2005.161
Abstract: Objectives: The Bath Ankylosing Spondylitis Functional Index (BASFI) and the Dougados Functional Index (DFI) are the most commonly used instruments to measure functioning in ankylosing spondylitis (AS). The aim of this study was to translate, adapt and validate these instruments into the Italian language. Methods: The BASFI and DFI questionnaires were translated into Italian by two independent bilingual physicians who were familiar with the medical aspects of AS and by one professional translator. Two rheumatologists familiar with instrument validation, and who were aware of the purpose of the study, examined semantic, idiomatic and conceptual issues and produced by consensus unified versions of each instrument. English back-translations from the Italian were done by a professional translator unaware of the original version. Both English versions were compared, and where needed, modifications to the Italian versions were made. Results: A total of 95 patients were included: 77 males, age (mean±SD) 47.9±9.3years, and disease duration 12.4±6.6 years, and 18 females, age 45.9±8.7 years, and disease duration 11.3±8.2 years. Reliability, measured in 23 patients participating a physiotherapy program, showed an acceptable one-week test-retest intraclass correlation coefficient (ICC) - BASFI ICC: 0.91, 95% CI: 0,87-0.94 and DFI ICC: 0.86, 95% CI: 0.83-0.90. The internal consistency was 0.90 (Cronbach’s alpha) for the BASFI and 0.87 for the DFI. For validity the functional indices were correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Patient Global Score (BAS-G), modified Health Assesment Questionnaire (HAQ-S), SF-36 physical component summary (SF-36 PCS), stiffness, pain, physician’s assessment of disease activity, Bath AS Radiology Index-total (BASRI-t), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). The functional indices (BASFI and DFI) were correlated with each other (p<0.0001) and with activity variables. There was no significant relationship between functional indices and BASRI-t and acute phase reactants. The receiver operating characteristic (ROC) curve analysis indicated that the BASFI ranked superior compared to HAQ-S, (p = 0.019) and SF36 PCS (p = 0.002), but not respect to DFI (p = NS), in distinguishing between patients with high and low disease activity. Conclusions: The Italian versions of the BASFI and DFI showed adequate reliability and validity in patients with AS. Because of psychometric advantages, the BASFI ma
Management of ankylosing spondylitis with infliximab
Éric Toussirot,Ewa Bertolini,Daniel Wendling
Open Access Rheumatology: Research and Reviews , 2009,
Abstract: éric Toussirot1,2,3, Ewa Bertolini1, Daniel Wendling1,21Rheumatology, University Hospital Jean Minjoz, Besan on, France; 2Equipe d’Accueil 3186 “Agents pathogènes et Inflammation” University of Franche-Comté, Besan on, France; 3CiC – Biotherapy, St-Jacques Hospital, Besan on, FranceAbstract: Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease responsible for back pain, stiffness and progressive loss of functional capacity with limited therapeutic options. Regular physical exercises together with the use of nonsteroidal antiinflammatory drugs are the two recognized treatment options in AS. Infliximab is a chimeric anti-tumor necrosis factor-α monoclonal antibody that has been demonstrated to be highly effective in the treatment of AS, providing clinical amelioration at both axial and peripheral skeleton. Infliximab also improves quality of life, function, biological parameters (acute phase reactants) and inflammatory lesions of the spine as detected by magnetic resonance imaging. It is given at a 5 mg/kg dosage, as an infusion at weeks 0, 2, 6, and every 6 to 8 weeks after. Open-label and placebo-controlled trials have well demonstrated its high level of efficacy, with an improvement of the disease activity of at least 50% in 60%–80% of patients. In a large placebo-controlled trial, Assessment in Ankylosing Spondylitis Response Criteria (ASAS20) responders were observed in 61.2% of patients receiving infliximab compared to 19.2% of patients under placebo. Long-term efficacy is maintained when infliximab is administered every 6–8 weeks. Consensus international guidelines for the initiation and the use of this expensive treatment are available. Some questions remain, including the long-term safety, in particular the risk of lymphoma, and the potential influence of infliximab on radiological progression which is not currently demonstrated. Despite these concerns, infliximab has revolutionized the management of AS and represents a considerable therapeutic advancement in this disabling disease.Keywords: anti-TNFα, infliximab, ankylosing spondylitis
Page 1 /100
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.